Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.37B 3.11B 2.9B 5.46B 364B 5.56B 37.28B 14.47B 179B 14.45B 14.13B 625B P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 3.85B 3.37B 3.11B 2.9B 5.46B 364B 5.56B 37.28B 14.47B 179B 14.45B 14.13B 625B EV / Sales 2026 *
6.05x
EV / Sales 2027 * 5.36x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day+0.02%
1 week+0.06%
Current month+0.03%
1 month+0.54%
3 months+26.67%
6 months+35.81%
Current year+34.70%
1 week 31.4
Extreme 31.4
31.5
1 month 31.25
Extreme 31.25
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Chairman 78 01/01/2002
Director/Board Member 62 01/10/2002
Director/Board Member 65 19/02/2015
Date Insider Type Main position Quantity % Market Cap.
03/06Fiscal year

Chief Technology Officer

3,795 0.0031%
17/02Fiscal year

Head of Human Resources

1,585 0.0013%
05/01Fiscal year

Chief Financial Officer

16,358 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+0.06%+48.37%+146.39% 3.85B
+1.12%+0.96%+17.67%-12.35% 63.44B
-1.87%+0.78%+54.03%+223.19% 56.98B
+0.36%+39.60%+39.60%+39.60% 41.58B
+3.16%+5.65%-50.57%-57.33% 38.01B
-1.34%+7.02%+64.22%-25.17% 31.9B
+3.90%+20.24%+153.23%-40.32% 27.79B
+0.21%+4.74%+65.29%+83.00% 22.65B
-0.56%+4.05%+1.53%+168.92% 17.64B
+1.00%-1.27%+63.11%+123.44% 16.49B
Average +0.59%+4.63%+45.65%+64.94% 32.03B
Weighted average by Cap. +0.55%+4.45%+40.47%+52.87%

Financials

2026 *2027 *
Net sales 636M 557M 514M 480M 903M 60.15B 920M 6.17B 2.39B 29.68B 2.39B 2.34B 103B 718M 628M 580M 541M 1.02B 67.88B 1.04B 6.96B 2.7B 33.5B 2.7B 2.64B 117B
Net income 231M 202M 187M 174M 328M 21.85B 334M 2.24B 870M 10.78B 868M 849M 37.57B 316M 277M 256M 238M 449M 29.9B 457M 3.06B 1.19B 14.75B 1.19B 1.16B 51.4B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
02/07/26 USD 31.44 +0.03% 234,392
30/06/26 USD 31.43 -0.10% 4,766,667
29/06/26 USD 31.46 -0.13% 1,752,851
26/06/26 USD 31.50 +0.25% 4,067,136
25/06/26 USD 31.42 0.00% 1,170,475
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.43USD
Average target price
31.67USD
Spread / Average Target
+0.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock